SCHEMBL1013735

SCHEMBL1013735

CON(C)C(=O)c1ccc(CN2[C@@H](C)COC[C@@H]2C)cc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.40
GPR119 Q8TDV5 4/20 0.39
MTOR P42345 1/20 0.38
HIF1A Q16665 1/20 0.37
EPAS1 Q99814 1/20 0.37
GRM2 Q14416 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
KMT2A Q03164 1/20 0.34
OPRK1 P41145 1/20 0.34
LTA4H P09960 1/20 0.34
PTGER4 P35408 1/20 0.34
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP3A4 P08684 1/20 0.33
MLNR O43193 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014953 1.00 MLYCD (0.40) MLYCDGPR119MTORHIF1AEPAS1
SCHEMBL1013734 1.00 MLYCD (0.40) MLYCDGPR119MTORHIF1AEPAS1
SCHEMBL13674546 0.83 LTA4H (0.46) GPR119MTORHIF1AEPAS1GRM2
SCHEMBL1014488 0.79 KMT2A (0.46) GRM2HDAC1HDAC6KMT2AOPRK1
SCHEMBL1013773 0.79 KMT2A (0.46) GRM2HDAC1HDAC6KMT2AOPRK1
SCHEMBL1070645 0.79 KMT2A (0.46) GRM2HDAC1HDAC6KMT2AOPRK1
SCHEMBL4268087 0.78 GRM2 (0.47) MTORGRM2HDAC1HDAC6KMT2A
SCHEMBL30134085 0.77 HDAC6 (0.44) MLYCDHIF1AEPAS1HDAC6KMT2A
SCHEMBL1014491 0.76 HIF1A (0.61) HIF1AEPAS1KMT2AMAPK1SMN1; SMN2
SCHEMBL16761855 0.73 MLYCD (0.51) MLYCDHDAC1HDAC6KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-02-10 US disclosed
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-02-10 US disclosed
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-02-10 US disclosed
EP-2272835-A1 NOVEL FIVE-MEMBERED RING COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-01-12 EP disclosed
EP-2272835-A1 NOVEL FIVE-MEMBERED RING COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND CCL11, CCR1, CCR10 MLYCD 4415/4885GPR119 772/4885MTOR 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.